My Companies
Notification
Account
Log Out
Login
Biocon signed global patent settlement with Genentech resolving all disputes over pertuzumab biosimilar Pebrilzo, securing earliest licensed launches in EU/UK in Q1 CY27, US in Q3 CY28 and RoW in CY26-28. Context: follows Sep CHMP positive, EC approval still pending.
Biocon Secures Japan Marketing Approval For Pegfilgrastim Biosimilar With Sandoz
Biocon Launches Yesafili Aflibercept Biosimilar in United States
Biocon Launches Yesafili Aflibercept Biosimilar Commercially In United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal